Colorado-based Ambrosia Biosciences secured $100 million in new financing to develop an oral small-molecule GLP-1 program. The funding supports continued preclinical and clinical development efforts as the company works to challenge entrenched peptide-based GLP-1 delivery methods. The investment highlights investor appetite for differentiated oral incretin biology at a time when multiple platforms are vying to replicate GLP-1 weight-loss outcomes in pill form. Ambrosia’s approach, centered on an oral small-molecule pathway, aims to address convenience, dosing logistics, and potential manufacturing efficiencies. If Ambrosia can translate potency and tolerability into clinical outcomes, it would strengthen the case for next-wave oral obesity and diabetes therapies alongside industry leaders expanding their own oral portfolios.